These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 23469877)

  • 21. Protective Vaccine Efficacy of the Complete Form of PPE39 Protein from Mycobacterium tuberculosis Beijing/K Strain in Mice.
    Kim A; Hur YG; Gu S; Cho SN
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Guérin vaccine.
    Pinto R; Saunders BM; Camacho LR; Britton WJ; Gicquel B; Triccas JA
    J Infect Dis; 2004 Jan; 189(1):105-12. PubMed ID: 14702160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.
    Dietrich J; Doherty TM
    APMIS; 2009 May; 117(5-6):440-57. PubMed ID: 19400867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of an Immune-Protective T-Cell Repertoire With Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans.
    Jeyanathan M; Damjanovic D; Yao Y; Bramson J; Smaill F; Xing Z
    J Infect Dis; 2016 Dec; 214(12):1996-2005. PubMed ID: 27703038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epitope promiscuity and population coverage of Mycobacterium tuberculosis protein antigens in current subunit vaccines under development.
    Ong E; He Y; Yang Z
    Infect Genet Evol; 2020 Jun; 80():104186. PubMed ID: 31923726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fc-based delivery system enhances immunogenicity of a tuberculosis subunit vaccine candidate consisting of the ESAT-6:CFP-10 complex.
    Farsiani H; Mosavat A; Soleimanpour S; Sadeghian H; Akbari Eydgahi MR; Ghazvini K; Sankian M; Aryan E; Jamehdar SA; Rezaee SA
    Mol Biosyst; 2016 Jun; 12(7):2189-201. PubMed ID: 27138226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
    Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
    PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The quest for a new vaccine against tuberculosis.
    Delogu G; Fadda G
    J Infect Dev Ctries; 2009 Feb; 3(1):5-15. PubMed ID: 19749443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of mutant mycobacteria as new vaccines to prevent tuberculosis.
    Hernàndez Pando R; Aguilar LD; Infante E; Cataldi A; Bigi F; Martin C; Gicquel B
    Tuberculosis (Edinb); 2006; 86(3-4):203-10. PubMed ID: 16542875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next-Generation Vaccines Based on Bacille Calmette-Guérin.
    Nieuwenhuizen NE; Kaufmann SHE
    Front Immunol; 2018; 9():121. PubMed ID: 29459859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and novel approaches to vaccine development against tuberculosis.
    Cayabyab MJ; Macovei L; Campos-Neto A
    Front Cell Infect Microbiol; 2012; 2():154. PubMed ID: 23230563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Promising Listeria-Vectored Vaccine Induces Th1-Type Immune Responses and Confers Protection Against Tuberculosis.
    Yin Y; Lian K; Zhao D; Tao C; Chen X; Tan W; Wang X; Xu Z; Hu M; Rao Y; Zhou X; Pan Z; Zhang X; Jiao X
    Front Cell Infect Microbiol; 2017; 7():407. PubMed ID: 29034213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycobacterium tuberculosis virulence: insights and impact on vaccine development.
    Delogu G; Provvedi R; Sali M; Manganelli R
    Future Microbiol; 2015; 10(7):1177-94. PubMed ID: 26119086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Testing of Tuberculosis Vaccine Candidates.
    Hatherill M; Tait D; McShane H
    Microbiol Spectr; 2016 Oct; 4(5):. PubMed ID: 28087924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tuberculosis vaccine types and timings.
    Orme IM
    Clin Vaccine Immunol; 2015 Mar; 22(3):249-57. PubMed ID: 25540272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in tuberculosis vaccine strategies.
    Skeiky YA; Sadoff JC
    Nat Rev Microbiol; 2006 Jun; 4(6):469-76. PubMed ID: 16710326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis.
    Billeskov R; Grandal MV; Poulsen C; Christensen JP; Winther N; Vingsbo-Lundberg C; Hoang TT; van Deurs B; Song YH; Aagaard C; Andersen P; Dietrich J
    Eur J Immunol; 2010 May; 40(5):1342-54. PubMed ID: 20186878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology.
    Kaufmann SHE
    Front Immunol; 2020; 11():316. PubMed ID: 32174919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
    Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
    Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.